The accelerator hypothesis: A review of the evidence for insulin resistance as the basis for type i as well as type II diabetes

International Journal of Obesity

Volumn 33, Issue 7, 2009, Pages 716-726

  Wilkin, T J ^a  

^a DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

Accelerator hypothesis; Diabetes; Insulin resistance; Overweight; Tempo

Indexed keywords

INSULIN;

ACCELERATOR HYPOTHESIS; ADULT; AUTOIMMUNITY; BODY WEIGHT; CHILD; CONCEPT FORMATION; DISEASE CLASSIFICATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HYPOTHESIS; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; WEIGHT GAIN; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EVIDENCE BASED MEDICINE; FEMALE; IMMUNOLOGY; INCIDENCE; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

BODY WEIGHT; CHILD; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INCIDENCE; INSULIN RESISTANCE; MALE; OBESITY; RISK FACTORS;

EID: 67650450153     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2009.97     Document Type: Review

References (91)

1. Molbak AG, Christau B, Marner B, Borch-Johnsen K, Nerup J. Incidence of insulin-dependent diabetes in age groups over 30 years in Denmark. Diabet Med 1994; 11: 650-655.
2. Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth. Diabetes Care 1999; 22: 345-354.
3. Aizawa T, Funase Y, Katakura M, Asanuma N, Yamauchi K, Yoshizawa K et al. Ketosis-onset diabetes in young adults with subsequent non-insulin-dependency, a link between IDDM and NIDDM? Diabet Med 1997; 14: 989-991.
4. Gale EA. Declassifying diabetes. Diabetologia 2006; 49: 1989- 1995.
5. Wilkin TJ. Changing perspectives in diabetes: their impact on its classification. Diabetologia 2007; 50: 1587-1592.
6. Wilkin TJ. The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia 2001; 44: 914-922.
7. Kibirige M,Metcalf B, Renuka R,Wilkin TJ. Testing the accelerator hypothesis: the relationship between body mass and age at diagnosis of type 1 diabetes. Diabetes Care 2003; 26: 2865-2870.
8. Betts P, Mulligan J, Ward P, Smith B, Wilkin TJ. Increasing body weight predicts the earlier onset of insulin-dependant diabetes in childhood: testing the 'accelerator hypothesis' (2). Diabet Med2005; 22: 144-151.
9. Knerr I, Wolf J, Reinehr T, Stachow R, Grabert M, Schober E et al.DPV Scientific Initiative of Germany and Austria. The 'accelerator hypothesis': relationship between weight, height, body mass index and age at diagnosis in a large cohort of 9248 German and Austrian children with type 1 diabetes mellitus. Diabetologia2005; 48: 2501-2504.
10. Kordonouri O, Hartmann R. Higher body weight is associated with earlier onset of type 1 diabetes in children: confirming the 'Accelerator Hypothesis'. Diabet Med 2005; 22: 1783-1784.
11. Clarke SL, Craig ME, Garnett SP, Chan AK, Cowell CT, Cusumano JM et al. Increased adiposity at diagnosis in younger children with type 1 diabetes does not persist. Diabetes Care 2006; 29: 1651-1653.
12. Dabelea D, D'Agostino Jr RB, Mayer-Davis EJ, Pettitt DJ, Imperatore G, Dolan LM et al. SEARCH for Diabetes in Youth Study Group. Testing the accelerator hypothesis: body size, betacell function, and age at onset of type 1(autoimmune) diabetes. Diabetes Care 2006; 29: 290-294.
13. Rosenbloom AL. Obesity, insulin resistance, beta-cell autoimmunity, and the changing clinical epidemiology of childhood diabetes. Diabetes Care 2003; 26: 2954-2956.
14. Daneman D. Is the 'accelerator hypothesis' worthy of our attention? Diabet Med 2005; 22: 115-117.
15. Gale EA. To boldly goFor to go too boldly? The accelerator hypothesis revisited. Diabetologia 2007; 50: 1571-1575.
16. Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. BMJ 2004; 27: 750-754.
17. GeptsW. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965; 14: 619-633.
18. Nerup J, Platz P, Anderssen OO. HLA antigens and diabetes mellitus. Lancet 1974; 2: 864-866.
19. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974; 2: 1279-1283.
20. Onkamo P, Vaananen S, Karvonen M, Tuomilehto J. Worldwide increase of type 1 diabetesFanalysis of the data on published incidence trends. Diabetologia 1999; 42: 1395-1403.
21. Gale EAM. The rise of childhood type 1 diabetes in the 20th century. Diabetes 2002; 51: 3353-3361.
22. Shuldiner AR, Yang R, Gong DW. Resistin, obesity and insulin resistanceFthe emerging role of the adipocyte as an endocrine organ. N Engl J Med 2001; 345: 1345-1346.
23. Moller DE, Flier JS. Insulin resistanceFmechanisms, syndromes, and implications. N Engl J Med 1991; 325: 938-948.
24. Navab M, Gharavi N, Watson AD. Inflammation and metabolic disorders. Curr Opin Clin Nutr Metab Care 2008; 11: 459-464.
25. Rastouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93 (11 Suppl 1): S64-S73.
26. Donath MY, Størling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med 2003; 81: 455-470.
27. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia 2005; 48: 1038-1050.
28. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27: 813-823.
29. Velho C, Froguel P. Maturity-onset diabetes of the young (MODY), MODY genes and non-insulin-dependent diabetes mellitus. Diabetes Metab 1997; 23 (Suppl 2): 34-37.
30. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006; 355: 467-477.
31. Sun Q, Yue P, Jeffrey A, Lumeng CN, Kampfrath T, Mikolaj MB et al. Ambient air pollution exaggerates adipose inflammation and insulin resistance in a mouse model of diet-induced obesity. Circulation 2009; 119: 538-546.
32. Saxena R, Gianniny L, Burtt NP, Lyssenko V, Giuducci C, Sjögren M et al. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes2006; 55: 2890-2895.
33. Maedler K, Donath MY. Beta-cells in type 2 diabetes: a loss of function and mass. Horm Res 2004; 62 (Suppl 3): 67-73.
34. Robertson RP, Harmon J, Tran PO, Poitout V. glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004; 53 (Suppl 1): S119-S124.
35. Wilkin TJ, Metcalf B, Jeffery A, Howdle S, Kirkby J, Voss LD. The relative contributions of birth weight, catch-up weight and current weight to the development of insulin resistance in contemporary children (EarlyBird 2). Diabetes 2002; 51: 3468-3472.
36. Gardner DS, Metcalf BS, Hosking J, Jeffery AN, Voss LD,Wilkin TJ. Trends, associations and predictions of insulin resistance in prepubertal children (EarlyBird 29). Pediatr Diabetes 2008; 9 (3 Part 1): 214-220.
37. Juneja R, Palmer JP. Type 1 1/2 diabetes: myth or reality? Autoimmunity 1999; 29: 65-83.
38. Gale EA. The rise of childhood type 1 diabetes in the 20th century. Diabetes 2002; 51: 3353-3361.
39. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? J Intern Med 2000; 247: 301-310.
40. Wilkin TJ. Early nutrition and diabetes mellitus (Editorial). BMJ1992; 306: 283-284.
41. Wilkin TJ. Autoimmunity: attack or defence? Autoimmunity 1989; 3: 57-73.
42. Grabar P. Autoantibodies and the physiological role of immunoglobulins. Immunol Today 1983; 4: 337-340.
43. Roitt I, Brostoff J, Male D. Immunology. Churchill Livingstone: London, 1995, pp 1.5-1.6.
44. Bjork E, Kampe O, Karlsson FA, Pipeleers DG, Andersson A, HellerströmCet al. Glucose regulation of the autoantigen GAD65 in human pancreatic islets. J Clin Endocrinol Metab 1992; 75: 574-576.
45. Judkowski V, Krakowski M, Rodriguez E, Mocnick L, Santamaria P, Sarvetnick N. Increased islet antigen presentation leads to type-1 diabetes in mice with autoimmune susceptibility. Eur J Immunol2004; 34: 1031-1040.
46. Xu P, Krischer JP, Cuthbertson D, Greenbaum C, Palmer JP. Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes Care 2007; 30: 2314-2320.
47. Fourlanos S, Harrison LC, Colman PG. The accelerator hypothesis and increasing incidence of type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2008; 15: 321-325.
48. Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC. Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 2004; 47: 1661-1667.
49. Hawa MI, Bonfanti R, Valeri C, Delli Castelli M, Beyan H, Leslie RD. No evidence for genetically determined alteration in insulin secretion or sensitivity predisposing to type 1 diabetes: a study of identical twins. Diabetes Care 2005; 28: 1415-1418.
50. Libman IM, Becker DJ. Coexistence of type 1 and type 2 diabetes mellitus: 'double' diabetes? Pediatr Diabetes 2003; 4: 110-113.
51. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulindependent onset of disease. Diabetes 1993; 42: 359-362.
52. Reinehr T, Schober E, Wiegand S, Thon A, Holl R. B-cell autoantibodies in children with type 2 diabetes mellitus: subgroup or misclassification? Arch Dis Child 2006; 91: 473-477.
53. Onkamo P, Vaananen S, Karvonen M, Tuomilehto J. Worldwide increase of type 1 diabetesFanalysis of the data on published incidence trends. Diabetologia 1999; 42: 1395-1403.
54. Baum JD, Ounsted M, Smith MA. Weight gain in infancy and subsequent development of diabetes mellitus in childhood. Lancet 1975; ii: 866.
55. Johansson C, Samuelsson U, Ludvigsson J. A high weight gain in early life is associated with an increased risk of type 1 (insulindependent) diabetes. Diabetologia 1994; 37: 91-94.
56. Hypponen E, Kenward MG, Virtanen SM, Piitulainen A, Virta- Autio P, Tuomilehto J et al. Infant feeding, early weight gain and risk of type 1 diabetes. Diabetes Care 1999; 22: 1961-1965.
57. Bruining GJ. Association between infant growth before onset of juvenile type-1 diabetes and autoantibodies to IA-2. Netherlands Kolibrie study group of childhood diabetes. Lancet 2000; 356: 655-656.
58. Hypponen E, Virtanen SM, Kenward MG, Knip M, Akerblom HK, Childhood Diabetes in Finland Study Group. Obesity, increased linear growth, and risk of type 1 diabetes in children. Diabetes Care 2000; 23: 1755-1760.
59. Pundziute-Lycka° A, Dahlquist G, Nyström L, Arnquist H, Björke E, Blohme' G et al. Swedish Childhood Diabetes Study Group. The incidence of Type I diabetes has not increased but shifted to a younger age at diagnosis in the 0-34 years group in Sweden 1983-1998. Diabetologia 2002; 45: 783-791.
60. Weets I, De Leeuw IH, Du Caju MV, Rooman R, Keymeulen B, Mathieu C et al. Belgian Diabetes Registry. The incidence of type 1 diabetes in the age group 0-39 years has not increased in Antwerp (Belgium) between 1989 and 2000: evidence for earlier disease manifestation. Diabetes Care 2002; 25: 840-846.
61. Hermann R, Knip M, Veijola R. Temporal changes in the frequencies of HLA genotypes in patients with type I diabetes- Findication of an increased environmental pressure? Diabetologia2003; 46: 420-425.
62. Gillespie KM, Bain SC, Barnett AH, Bingley PJ, Christie MR, Gill GVet al. The rising incidence of type 1 diabetes is associated with a reduced contribution from high-risk HLA haplotypes. Lancet2004; 364: 1699-1700.
63. Leslie RD, Taylor R, Pozzilli P. The role of insulin resistance in the natural history of type 1 diabetes. Diabet Med 1997; 14: 327-331.
64. Greenbaum CJ. Insulin resistance and type 1 diabetes. Diabetes Metab Res Rev 2002; 18: 192-200.
65. Gale EA. Spring harvest? Reflections on the rise of type 1 diabetes. Diabetologia 2005; 48: 2445-2450.
66. Greenbaum CJ, Eisenbarth G, Atkinson M, Yu L, Babu S, Schatz D et al. DPT-1 study group. High frequency of abnormal glucose tolerance in DQA1*0102/DQB1*0602 relatives identified as part of the Diabetes Prevention Trial. Diabetologia 2005; 48: 68-74.
67. Irvine WJ, McCallum CJ, Gray RS, Duncan LJ. Clinical and pathogenic significance of pancreatic-islet-cell antibodies in diabetics treated with oral hypoglycaemic agents. Lancet 1977; 1: 1025-1027.
68. Hathout EH, Thomas W, El-Shahawy M, Nahab F, Mace JW. Diabetic autoimmune markers in children and adolescents with type 2 diabetes. Pediatrics 2001; 107: E102.
69. Umpaichitra V, Banerji MA, Castells S. Autoantibodies in children with type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2002; 15(Suppl 1): 525-530.
70. Gilliam LK, Brooks-Worrell BM, Palmer JP, Greenbaum CJ, Pihoker C. Autoimmunity and clinical course in children with type 1, type 2, and type 1.5 diabetes. J Autoimmun 2005; 25: 244-250.
71. Brooks-Worrell BM, Greenbaum CJ, Palmer JP, Pihoker C. Autoimmunity to islet proteins in children diagnosed with new-onset diabetes. J Clin Endocrinol Metab 2004; 89: 2222-2227.
72. Ziegler AG, Hummel M, Schenker M, Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 1999; 48: 460-468.
73. Porter JR, Barrett TJ. Braking the accelerator hypothesis? Diabetologia 2004; 47: 352-353.
74. Tait BD, Harrison LC, Drummond BP, Stewart V, Varney MD, Honeyman MC. HLA antigens and age at diagnosis of insulindependent diabetes mellitus. Hum Immunol 1995; 42: 116-122.
75. Bingley PJ, Mahon JL, Gale EA, The European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 2008; 31: 146-150.
76. Wilkin TJ. Testing the accelerator hypothesis: body size, beta-cell function, and age at onset of type 1 (autoimmune) diabetes: response to Dabelea et al. Diabetes Care 2006; 29: 1462-1463.
77. Wilkin TJ. Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT): response to Bingley et al. Diabetologia 2008; 31: e290.
78. Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006; 355: 241-250.
79. Field SF, Howson JMM, Smyth DJ, Walker NM, Dunger DB, Todd JA. Analysis of the type 2 diabetes gene TCF7L2 in 13 795 type 1 diabetes cases and control subjects. Diabetologia 2007; 50: 212-213.
80. Wilkint TJ. The accelerator hypothesis cannot be tested using the type 2 diabetes gene, TCF7L2. Diabetologia 2007; 50: 1780.
81. Field SF, Howson JM, Walker NM, Dunger DB, Todd JA. Analysis of the obesity gene FTO in 14 803 type 1 diabetes cases and controls. Diabetologia 2007; 50: 2218-2220.
82. O'connell MA, Donath S, Cameron FJ. Major increase in type 1 diabetesFno support for the accelerator hypothesis. Diabet Med2007; 24: 920-923.
83. Wilkin T. Major increase in type 1 diabetes: no support for the accelerator hypothesis (response to O'Connell et al). Diabet Med2008; 25: 376-377.
84. Dahlquist G. The aetiology of type 1 diabetes: an epidemiological perspective. Acta Paediatr 1998; 425 (Suppl): 5-10.
85. Day C. Thiazolidinediones. Diabetic Med 1999; 16: 179.92.
86. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
87. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med2001; 344: 1343-1350.
88. Harlan DM, von Herrath M. Immune intervention with anti-CD3 in diabetes. Nat Med 2005; 11: 716-718.
89. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D et al. Single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54: 1763-1769.
90. Dupre J, Stiller CR, Gent M, Donner A, von Graffenried B, Heinrichs D et al. Clinical trials of cyclosporin in IDDM. Diabetes Care 1988; 11 (Suppl 1): 37-44.
91. Wilkin T, Ludvigsson J, Greenbaum C, Palmer J, Becker D, Bruining J. Future intervention trials in type 1 diabetes. Diabetes Care 2004; 27: 996-997.